Molecule linked to aggressive pancreatic cancer offers potential clinical advances

Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient. They say the study provides key insights into the most aggressive form of the disease, which is one of the deadliest human cancers. It also offers a number of possible future clinical advances, such as a way to gauge outcome in individual patients, and insight into potential therapy to shut down activity of the enzyme, known as Rac1b. Read more here.